Meeting
2017 Gastrointestinal Cancers Symposium
Antitumor activity of panRAF inhibition in BRAF V600E metastatic colorectal cancer.
Authors
Alex Sorokin
MD Anderson Cancer Center, Houston, TX
Alex Sorokin , Lea Bitner , Ji Wu , David Menter , Scott Kopetz , Van Karlyle Morris II
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session C: Cancers of the Colon, Rectum, and Anus
Track
Cancers of the Colon, Rectum, and Anus
Sub Track
Translational Research
Citation
J Clin Oncol 35, 2017 (suppl 4S; abstract 616)
DOI
10.1200/JCO.2017.35.4_suppl.616
Abstract #
616
Poster Bd #
E12
Abstract Disclosures
Similar Posters
Poster
2016 Gastrointestinal Cancers Symposium
Role of MEK inhibition in improving anti-tumor responses in xenograft models of BRAF-mutated metastatic colorectal cancer.
First Author: Van Karlyle Morris II
Poster
2014 ASCO Annual Meeting
Antitumor effects of dabrafenib, trametinib, and panitumumab as single agents and in combination in BRAF-mutant colorectal carcinoma (CRC) models.
First Author: LI Liu
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Genomic alterations associated with resistance to EGFR monoclonal antibodies (mAb) in real-world patients with metastatic colorectal cancer (mCRC).
First Author: Samuel J Klempner
Poster
2022 ASCO Annual Meeting
NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status.
First Author: Samuel A. Jacobs